NASDAQ:MYL - Mylan Stock Price, Price Target & More

Get Started

$39.66 -0.42 (-1.05 %)

(As of 05/20/2018 04:00 PM ET)

Previous Close$39.66

Today's Range$39.55 - $40.26

52-Week Range$29.39 - $47.82

Volume4.59 million shs

Average Volume4.75 million shs

Market Capitalization$20.44 billion

P/E Ratio8.70

Dividend YieldN/A

Beta1.35

About Mylan (NASDAQ:MYL)

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; anti-retroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology, oncology, and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; and Dymista, which is used for the treatment of seasonal allergic rhinitis. Further, it markets OTC products, including Cold-EEZE, Midnite, and Vivarin. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, group purchasing organizations, and government entities; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. Mylan N.V. has collaboration and license agreements with Pfizer Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., and Biocon Ltd. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:MYL

CUSIP62853010

Webwww.mylan.com

Phone44-0-17-0785-3000

Debt

Debt-to-Equity Ratio1.03

Current Ratio1.06

Quick Ratio0.65

Price-To-Earnings

Trailing P/E Ratio8.70

Forward P/E Ratio7.40

P/E Growth1.29

Sales & Book Value

Annual Sales$11.91 billion

Price / Sales1.72

Cash Flow$7.9162 per share

Price / Cash5.01

Book Value$25.56 per share

Price / Book1.55

Profitability

EPS (Most Recent Fiscal Year)$4.56

Net Income$696 million

Net Margins6.04%

Return on Equity18.56%

Return on Assets6.86%

Miscellaneous

Employees35,000

Outstanding Shares515,450,000

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) posted its quarterly earnings data on Wednesday, May, 9th. The company reported $0.96 earnings per share for the quarter, missing analysts' consensus estimates of $0.99 by $0.03. The firm earned $2.68 billion during the quarter, compared to analysts' expectations of $2.74 billion. Mylan had a net margin of 6.04% and a return on equity of 18.56%. The business's quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.93 earnings per share. View Mylan's Earnings History.

When is Mylan's next earnings date?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Mylan.

What guidance has Mylan issued on next quarter's earnings?

Mylan issued an update on its FY18 earnings guidance on Wednesday, May, 9th. The company provided earnings per share guidance of $5.20-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.37. The company issued revenue guidance of $11.75-13.25 billion, compared to the consensus revenue estimate of $12.43 billion.

What price target have analysts set for MYL?

19 equities research analysts have issued 1-year price objectives for Mylan's stock. Their predictions range from $29.39 to $59.00. On average, they expect Mylan's stock price to reach $47.2311 in the next year. View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:

1. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) The North America segment was down 8%, excluding Epipen, which declined $131.9MM in 4Q17, and $655.4MM in 2017. EU grew 16% in the quarter, and Rest of World grew 12%. 2) Generic drug pricing continued to be a headwind in the U.S. during the quarter. However, favorable pricing on existing products in Europe was a tailwind in 4Q17. 3) The Restasis target action date is in July 2018. The Biosimilar pegfilgrastim target action date is in early June. 4) MYL repurchased 12.4MM shares during 2017, and an additional 9.8MM shares in January 2018. 4) MYL expects to launch generic Adavir and Neulasta in 2018, and has risk-weighted these launches in its 2018 guidance." (3/1/2018)
2. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018)
3. Argus analysts commented, "junior version" (8/22/2017)

Are investors shorting Mylan?

Mylan saw a decline in short interest in April. As of April 30th, there was short interest totalling 18,066,577 shares, a decline of 8.3% from the April 13th total of 19,711,829 shares. Based on an average trading volume of 3,357,325 shares, the short-interest ratio is presently 5.4 days. Approximately 3.7% of the company's stock are short sold.

Who are some of Mylan's key competitors?

Some companies that are related to Mylan include Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Grifols (GRFS), UCB (UCBJF) and Nektar Therapeutics (NKTR).

Who are Mylan's key executives?

Mylan's management team includes the folowing people:

Ms. Heather Bresch, CEO & Exec. Director (Age 49)
Mr. Rajiv Malik, Pres & Exec. Director (Age 57)
Mr. Kenneth S. Parks, Chief Financial Officer (Age 55)
Mr. Daniel M. Gallagher Jr., Chief Legal Officer (Age 45)
Mr. Anthony Mauro, Chief Commercial Officer (Age 45)

Has Mylan been receiving favorable news coverage?

News headlines about MYL stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mylan earned a news impact score of 0.18 on Accern's scale. They also assigned media coverage about the company an impact score of 50.21 out of 100, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days.

Who are Mylan's major shareholders?

Mylan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.75%), Pzena Investment Management LLC (4.14%), First Pacific Advisors LLC (1.84%), FIL Ltd (1.07%), Northern Trust Corp (1.06%) and Dimensional Fund Advisors LP (0.87%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Joseph C Md Maroon, Laboratories Abbott, Paul Campbell, Rajiv Malik, Robert J Cindrich and Robert J Coury. View Institutional Ownership Trends for Mylan.

Which major investors are selling Mylan stock?

MYL stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Point72 Asset Management L.P., Migdal Insurance & Financial Holdings Ltd., Clal Insurance Enterprises Holdings Ltd, Prudential Financial Inc., Pzena Investment Management LLC, BlackRock Inc. and State of Wisconsin Investment Board. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan.

Which major investors are buying Mylan stock?

MYL stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Lord Abbett & CO. LLC, Korea Investment CORP, Neuberger Berman Group LLC, DekaBank Deutsche Girozentrale, Massachusetts Financial Services Co. MA, Redmile Group LLC and FIL Ltd. Company insiders that have bought Mylan stock in the last two years include Joseph C Md Maroon and Robert J Cindrich. View Insider Buying and Selling for Mylan.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $39.66.

How big of a company is Mylan?

Mylan has a market capitalization of $20.44 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

How can I contact Mylan?

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]

MarketBeat Community Rating for Mylan (MYL)

Community Ranking:		2.9 out of 5 ( )
Outperform Votes:		594 (Vote Outperform)
Underperform Votes:		434 (Vote Underperform)
Total Votes:		1,028

MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Mylan (NASDAQ:MYL) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Mylan in the last 12 months. Their average twelve-month price target is $47.2311, suggesting that the stock has a possible upside of 19.09%. The high price target for MYL is $59.00 and the low price target for MYL is $29.39. There are currently 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.74	2.74	2.63	2.61
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$47.2311	$47.2311	$45.0732	$41.2744
Price Target Upside:	19.09% upside	15.59% upside	8.22% upside	10.39% upside

Mylan (NASDAQ:MYL) Consensus Price Target History

Price Target History for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/9/2018	Cantor Fitzgerald	Set Price Target	Hold	$41.00	Low
4/23/2018	Wells Fargo	Reiterated Rating	Hold		Low
4/12/2018	JPMorgan Chase	Set Price Target	Buy	$53.00	Low
4/12/2018	Leerink Swann	Upgrade	Market Perform ➝ Outperform	$44.00	Low
4/9/2018	Morgan Stanley	Set Price Target	Buy	$50.00	High
4/3/2018	Royal Bank of Canada	Set Price Target	Hold	$45.00	Low
3/15/2018	Mizuho	Boost Price Target	Buy	$45.00 ➝ $51.00	Low
3/1/2018	UBS	Set Price Target	Buy	$54.00	High
1/25/2018	Susquehanna Bancshares	Reiterated Rating	Positive ➝ Positive	$47.00 ➝ $55.00	Low
1/24/2018	Deutsche Bank	Set Price Target	Buy	$50.00	Low
1/11/2018	Goldman Sachs	Boost Price Target	Buy	$46.00 ➝ $52.00	High
1/4/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $58.00	High
12/12/2017	Guggenheim	Initiated Coverage	Buy ➝ Buy	$59.00	Low
10/5/2017	Instinet	Reiterated Rating	Buy	$37.00	N/A
10/5/2017	Cowen	Reiterated Rating	Market Perform	$30.00 ➝ $36.00	N/A
10/4/2017	BTIG Research	Boost Price Target	Buy ➝ Buy	$42.00 ➝ $45.00	High
9/29/2017	BMO Capital Markets	Reiterated Rating	Buy	$45.00	Low
8/22/2017	Argus	Downgrade	Buy ➝ Hold	$47.59 ➝ $29.39	Low
5/22/2017	Barclays	Upgrade	Equal Weight ➝ Overweight	$47.00 ➝ $50.00	Low
12/30/2016	Stifel Nicolaus	Reiterated Rating	Positive		N/A
10/10/2016	Raymond James	Upgrade	Market Perform ➝ Strong-Buy	$57.00	N/A
9/23/2016	Sanford C. Bernstein	Set Price Target	Buy	$60.00	N/A
8/26/2016	Evercore ISI	Reiterated Rating	Hold	$49.00	N/A
8/24/2016	Bank of America	Reiterated Rating	Buy	$70.00	N/A

(Data available from 5/20/2016 forward)

Mylan (NASDAQ:MYL) Earnings History and Estimates Chart

Earnings by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Earnings Estimates

2018 EPS Consensus Estimate: $5.36

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	$0.92	$0.92	$0.92
Q2 2018	1	$1.28	$1.28	$1.28
Q3 2018	1	$1.43	$1.43	$1.43
Q4 2018	1	$1.73	$1.73	$1.73

Mylan (NASDAQ MYL) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/7/2018		$1.24					N/A
5/9/2018	Q1 2018	$0.99	$0.96	$2.7389 billion	$2.6845 billion	View	N/A
2/28/2018	Q4 2017	$1.41	$1.43	$3.2910 billion	$3.2390 billion	View	Listen
11/6/2017	Q3 2017	$1.20	$1.10	$3.0927 billion	$2.9871 billion	View	N/A
8/9/2017	Q2 2017	$1.18	$1.10	$2.9975 billion	$2.9622 billion	View	Listen
5/10/2017	Q1 17	$0.92	$0.93	$2.8130 billion	$2.7195 billion	View	N/A
3/1/2017	Q4 2016	$1.42	$1.57	$3.1754 billion	$3.2678 billion	View	N/A
11/9/2016	Q3 2016	$1.50	$1.38	$3.12 billion	$3.06 billion	View	Listen
8/9/2016	Q216	$1.13	$1.16	$2.58 billion	$2.56 billion	View	N/A
5/3/2016	Q116	$0.74	$0.76	$2.23 billion	$2.19 billion	View	N/A
2/10/2016	Q415	$1.27	$1.22	$2.71 billion	$2.4907 billion	View	Listen
10/30/2015	Q315	$1.38	$1.43	$2.79 billion	$2.71 billion	View	Listen
8/6/2015	Q215	$0.89	$0.91	$2.39 billion	$2.37 million	View	N/A
5/5/2015	Q115	$0.70	$0.70	$2.2220 billion	$1.8717 billion	View	Listen
3/2/2015	Q414	$1.05	$1.05	$2.07 billion	$2.08 billion	View	Listen
10/30/2014	Q314	$1.14	$1.16	$2.06 billion	$2.08 billion	View	N/A
8/7/2014	Q214	$0.70	$0.69	$1.88 billion	$1.84 billion	View	N/A
5/1/2014	Q114	$0.63	$0.66	$1.80 billion	$1.72 billion	View	N/A
2/27/2014	Q413	$0.75	$0.78	$1.81 billion	$1.81 billion	View	N/A
10/31/2013	Q313	$0.79	$0.82	$1.84 billion	$1.77 billion	View	N/A
8/1/2013	Q2 2013	$0.67	$0.68	$1.73 billion	$1.70 billion	View	N/A
5/2/2013	Q1 2013	$0.62	$0.62	$1.6939 billion	$1.6315 billion	View	N/A
2/27/2013	Q4 2012	$0.64	$0.65	$1.73 billion	$1.72 billion	View	N/A
10/25/2012		$0.77	$0.83			View	N/A
7/26/2012		$0.55	$0.60			View	N/A
4/26/2012		$0.51	$0.52			View	N/A
2/21/2012		$0.50	$0.53			View	N/A
10/26/2011		$0.51	$0.55			View	N/A
7/27/2011		$0.45	$0.52			View	N/A
5/3/2011		$0.44	$0.44			View	N/A
2/24/2011		$0.45	$0.45			View	N/A
10/26/2010	Q3 2010	$0.42	$0.43			View	N/A
7/28/2010	Q2 2010	$0.38	$0.37			View	N/A
4/29/2010	Q1 2010	$0.34	$0.36			View	N/A
2/25/2010	Q4 2009	$0.30	$0.33			View	N/A
10/29/2009	Q3 2009	$0.27	$0.32			View	N/A
7/30/2009	Q2 2009	$0.29	$0.32			View	N/A
4/30/2009	Q1 2009	$0.27	$0.22			View	N/A
2/19/2009	Q4 2008	$0.14	$0.26			View	N/A
10/30/2008	Q3 2008	$0.12	$0.23			View	N/A
8/6/2008	Q2 2008	$0.10	$0.16			View	N/A
5/8/2008	Q1 2008	$0.08	$0.09			View	N/A
2/27/2008	Q4 2007	($0.06)	$0.11			View	N/A

(Earnings results data provided by Zacks Investment Research)

Mylan (NASDAQ:MYL) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Mylan (NASDAQ MYL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 83.53%

Insider Trading History for Mylan (NASDAQ:MYL)

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2018	Paul Campbell	Insider	Sell	7,030	$44.01	$309,390.30	17,054
3/6/2018	Robert J. Coury	Director	Sell	50,000	$43.41	$2,170,500.00
3/2/2018	Anthony Mauro	Insider	Sell	12,257	$40.35	$494,569.95	147,435
3/2/2018	Rajiv Malik	President	Sell	50,000	$40.91	$2,045,500.00	503,751
3/2/2018	Robert J. Coury	Director	Sell	150,000	$40.10	$6,015,000.00
1/9/2018	Heather M. Bresch	CEO	Sell	75,000	$45.00	$3,375,000.00
6/9/2017	Anthony Mauro	Insider	Sell	10,000	$40.00	$400,000.00	140,653
6/9/2017	Rajiv Malik	President	Sell	25,000	$40.00	$1,000,000.00	799,855
3/23/2017	Laboratories Abbott	Major Shareholder	Sell	44,000,000	$41.60	$1,830,400,000.00
8/9/2016	Heather M Bresch	CEO	Sell	100,200	$50.00	$5,010,000.00	828,318
6/3/2016	Joseph C Md Maroon	Director	Buy	1,670	$44.95	$75,066.50	22,036
5/25/2016	Robert J Cindrich	Director	Buy	1,190	$42.47	$50,539.30	13,384
5/12/2016	Melina E Higgins	Director	Buy	19,900	$38.68	$769,732.00	1,872
5/6/2016	Melina E Higgins	Director	Buy	100	$38.69	$3,869.00	1,872
4/28/2016	Melina E Higgins	Director	Buy	35,000	$42.92	$1,502,200.00
4/5/2016	Robert J Coury	Chairman	Sell	217,755	$45.96	$10,008,019.80	1,334,306
3/31/2016	Joseph C Md Maroon	Director	Buy	4,337	$46.36	$201,063.32	16,124
3/17/2016	Mark W Parrish	Director	Buy	1,705	$44.00	$75,020.00	31,365
3/8/2016	Wendy Cameron	Director	Buy	2,190	$45.69	$100,061.10	66,677
3/3/2016	Robert J Cindrich	Director	Buy	2,187	$45.83	$100,230.21	10,322
12/17/2015	John D. Sheehan	CFO	Sell	34,579	$55.03	$1,902,882.37	171,251
6/15/2015	Melina E Higgins	Director	Sell	8,351	$73.08	$610,291.08
2/3/2015	Anthony Mauro	Insider	Sell	13,255	$53.15	$704,503.25
2/3/2015	Heather M Bresch	CEO	Sell	411,996	$53.15	$21,897,587.40
2/3/2015	Rajiv Malik	President	Sell	285,394	$53.15	$15,168,691.10
2/3/2015	Robert J Coury	Chairman	Sell	947,119	$52.55	$49,771,103.45
2/3/2015	Rodney L Piatt	Director	Sell	46,000	$53.15	$2,444,900.00
11/26/2014	John D Sheehan	CFO	Sell	19,475	$57.50	$1,119,812.50
11/25/2014	Heather M Bresch	CEO	Sell	100,000	$55.80	$5,580,000.00
11/25/2014	Rajiv Malik	President	Sell	120,000	$55.78	$6,693,600.00
11/25/2014	Robert J Coury	Chairman	Sell	165,700	$55.78	$9,242,746.00
11/24/2014	Heather M Bresch	CEO	Sell	80,222	$55.86	$4,481,200.92
11/24/2014	Rajiv Malik	President	Sell	84,300	$55.86	$4,708,998.00
11/24/2014	Robert J Coury	Chairman	Sell	105,800	$55.88	$5,912,104.00
11/7/2014	Melina E Higgins	Director	Buy	14,000	$52.45	$734,300.00
9/18/2014	Neil F Dimick	Director	Sell	5,432	$48.26	$262,148.32
6/19/2014	Neil F Dimick	Director	Sell	5,432	$50.81	$275,999.92
4/22/2014	Rajiv Malik	President	Sell	80,000	$50.00	$4,000,000.00	289,117
4/14/2014	Heather Bresch	CEO	Sell	75,000	$46.07	$3,455,250.00	293,418
3/20/2014	Neil Dimick	Director	Sell	5,813	$53.08	$308,554.04	32,136
3/14/2014	C Todd	Director	Sell	10,000	$53.00	$530,000.00	23,389
3/6/2014	Harry Korman	COO	Sell	31,970	$54.54	$1,743,643.80	133,373
3/3/2014	Anthony Mauro	Insider	Sell	20,000	$54.81	$1,096,200.00	25,473
3/3/2014	Daniel Rizzo, Jr.	CAO	Sell	8,003	$55.50	$444,166.50	82,296
3/3/2014	Douglas Leech	Director	Sell	10,000	$55.40	$554,000.00	36,271
1/2/2014	Neil Dimick	Director	Sell	5,813	$43.15	$250,830.95	32,136
12/19/2013	Rodney Piatt	Director	Sell	10,000	$41.84	$418,400.00	62,436
12/12/2013	Daniel Rizzo, Jr.	CAO	Sell	70,683	$42.04	$2,971,513.32	68,971
12/12/2013	Melina Higgins	Director	Buy	5,000	$42.03	$210,150.00
9/6/2013	Heather M Bresch	CEO	Sell	160,000	$35.35	$5,656,000.00
6/3/2013	Neil F Dimick	Director	Sell	19,994	$30.51	$610,016.94
11/27/2012	Daniel C Rizzo Jr	CAO	Sell	161,124	$27.28	$4,395,462.72
11/2/2012	Douglas J Leech	Director	Sell	44,280	$25.94	$1,148,623.20
11/1/2012	Anthony Mauro	Insider	Sell	12,301	$25.79	$317,242.79
10/5/2012	Anthony Mauro	Insider	Sell	12,296	$24.84	$305,432.64

(Data available from 1/1/2013 forward)

Mylan (NASDAQ MYL) News Headlines

Source:

Date	Headline
	Why Mylan NV.’s (NASDAQ:MYL) ROE Of 5.44% Does Not Tell The Whole Story finance.yahoo.com - May 19 at 8:45 AM
	Mylan (MYL) Expected to Post Quarterly Sales of $3.00 Billion www.americanbankingnews.com - May 19 at 3:02 AM
	Mylan Target of Unusually High Options Trading (MYL) www.americanbankingnews.com - May 18 at 6:46 AM
	Mylan (MYL): Biocon's Bangalore Facility Re-Inspections Likely Not Required, Observations Benign - Guggenheim www.streetinsider.com - May 17 at 5:15 PM
	Zacks: Brokerages Anticipate Mylan (MYL) Will Announce Earnings of $1.23 Per Share www.americanbankingnews.com - May 17 at 1:14 PM
	Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1 finance.yahoo.com - May 16 at 5:22 PM
	Mylan N.V. -- Moody's assigns Baa3 to Mylan's Euro offering finance.yahoo.com - May 16 at 5:22 PM
	Mylan (MYL) Upgraded to "Hold" at BidaskClub www.americanbankingnews.com - May 16 at 10:30 AM
	Mylan Inc. -- Moody's assigns Baa3 to Mylan's Euro offering finance.yahoo.com - May 16 at 9:10 AM
	Proctor & Gamble, Mylan And More Stocks Sending Strong Signals This Week www.benzinga.com - May 14 at 5:14 PM
	Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE finance.yahoo.com - May 14 at 5:14 PM
	Mylan Critic Blumenthal Asks FDA to Help End EpiPen Shortage finance.yahoo.com - May 14 at 5:14 PM
	Mylan (MYL) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - May 14 at 11:14 AM
	Department of Justice seeks information from Mylan finance.yahoo.com - May 14 at 9:57 AM
	Mylan to Post Q2 2018 Earnings of $1.28 Per Share, Leerink Swann Forecasts (MYL) www.americanbankingnews.com - May 14 at 2:02 AM
	Mylan (MYL) Sees Large Decline in Short Interest www.americanbankingnews.com - May 13 at 1:40 AM
	Big pharma stocks unfazed by Trump speech finance.yahoo.com - May 12 at 8:52 AM
	Q3 2018 EPS Estimates for Mylan (MYL) Reduced by Analyst www.americanbankingnews.com - May 11 at 10:15 AM
	BRIEF-Mylan Says Non-Contingent Payments For 4 Agreements Total About $265 Mln www.reuters.com - May 11 at 9:30 AM
	DoJ investigates Mylan on trade compliance for certain products www.reuters.com - May 11 at 9:30 AM
	BMO Capital Reiterates Outperform on Mylan (MYL) Following Mixed 1Q www.streetinsider.com - May 10 at 5:15 PM
	Use an EpiPen? FDA notes some shortages of injector used to treat allergies, bug bites www.usatoday.com - May 10 at 5:15 PM
	Edited Transcript of MYL earnings conference call or presentation 9-May-18 2:00pm GMT finance.yahoo.com - May 10 at 5:14 PM
	Epipen shortage should be short term: Mylan www.cnbc.com - May 10 at 8:43 AM
	Mylan (MYL) Posts Quarterly Earnings Results, Hits Estimates www.americanbankingnews.com - May 9 at 6:14 PM
	FDA adds Mylan's EpiPen to shortage list www.reuters.com - May 9 at 5:17 PM
	BRIEF-Mylan Reports Q1 Adjusted Earnings Per Share Of $0.96 www.reuters.com - May 9 at 5:17 PM
	Mylan First-Quarter Revenue Misses Estimate Amid Lower Sales of Branded Product www.thestreet.com - May 9 at 5:17 PM
	Mylan May Be Gem in Rough Generic Sector www.wsj.com - May 9 at 5:17 PM
	FDA says Mylan's EpiPen is in shortage in US www.reuters.com - May 9 at 5:17 PM
	[$$] Mylan May Be Gem in Rough Generic Sector finance.yahoo.com - May 9 at 5:17 PM
	FDA says Mylan's EpiPen is in shortage in U.S. finance.yahoo.com - May 9 at 5:17 PM
	FDA reports some EpiPen shortages due to manufacturing delays finance.yahoo.com - May 9 at 5:17 PM
	Mylan's 1st Quarter Results Are Weaker Than They Might Seem finance.yahoo.com - May 9 at 5:17 PM
	Mylan (MYL) Q1 Earnings Lag on Weak North America Sales finance.yahoo.com - May 9 at 5:17 PM
	Mylan (MYL) Given a $41.00 Price Target at Cantor Fitzgerald www.americanbankingnews.com - May 9 at 3:17 PM
	Mylan's 1st Quarter Results Are Weaker Than They Might Seem www.fool.com - May 9 at 2:52 PM
	Mylan NV Stock Up Despite Q1 Earnings and Revenue Miss investorplace.com - May 9 at 1:21 PM
	Mylan (MYL) Updates FY18 Earnings Guidance www.americanbankingnews.com - May 9 at 8:59 AM
	Mylan Q1 non-GAAP EPS up 3%; reaffirms guidance seekingalpha.com - May 9 at 8:38 AM
	Mylan's quarterly profit rises 31 percent www.nasdaq.com - May 9 at 8:38 AM
	Mylan shares drop 2% after Q1 revenue miss www.marketwatch.com - May 9 at 8:38 AM
	Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance www.prnewswire.com - May 9 at 8:38 AM
	Reports of EpiPen shortage unfounded, Mylan says www.cnn.com - May 9 at 8:38 AM
	Will The U.S. Senate Candidates Cater To The Past Or Will West Virginia's Coal Economy Evolve? finance.yahoo.com - May 9 at 8:38 AM
	Mylan misses revenue estimates as EpiPen sales dip finance.yahoo.com - May 9 at 8:38 AM
	FDA says manufacturing delays are constraining EpiPen supply finance.yahoo.com - May 9 at 8:38 AM
	Mylan says EpiPen supply levels may vary at U.S. pharmacies finance.yahoo.com - May 8 at 5:19 PM
	Mylan (MYL) vs. The Competition Financial Survey www.americanbankingnews.com - May 8 at 12:34 PM
	Mylan (MYL) to Report Q1 Earnings: What's in the Offing? www.zacks.com - May 7 at 5:16 PM